Sarepta Therapeutics Inc
NASDAQ:SRPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Irm Energy Ltd
NSE:IRMENERGY
|
IN |
|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
CN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-70.57 (441% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.2 | $20.68 |
0%
|
| Industry Average | 14.3 | $-70.57 |
-441%
|
| Country Average | 19.6 | $-97.01 |
-569%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$2.3B
|
/ |
Jan 2026
$-492.5m
|
= |
|
|
$2.3B
|
/ |
Dec 2026
$326.5m
|
= |
|
|
$2.3B
|
/ |
Dec 2027
$195.6m
|
= |
|
|
$2.3B
|
/ |
Dec 2028
$110.7m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
2.2B USD | -4.2 | -3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 20 | 86.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 15 | 19.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 42.2 | 38.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Sarepta Therapeutics Inc
Glance View
Sarepta Therapeutics Inc. is a company firmly rooted in the ambitious quest to change the lives of those grappling with rare genetic disorders, particularly focusing on Duchenne muscular dystrophy (DMD). The scientists and innovators at Sarepta are driven by their expertise in genetic medicine, utilizing cutting-edge technologies such as exon skipping, gene therapy, and RNA-targeted therapeutics to develop treatments that combat the underlying causes of these debilitating diseases. The company's journey is underscored by its commitment to not only advancing science but also accelerating the delivery of hope to patients and families affected by these life-limiting conditions. Central to Sarepta's business model is the commercialization of its approved therapies, alongside an expansive pipeline of potential treatments still in various stages of research and development. By prioritizing strategic partnerships and leveraging their robust intellectual property portfolio, Sarepta translates pioneering science into tangible healthcare solutions. Revenue is chiefly generated through the sales of its FDA-approved DMD treatments, capturing a market niche due to the lack of viable alternatives. As Sarepta looks toward future horizons, the company remains steadfast in its mission to scale new heights in genetic medicine, aiming to redefine the standard of care for rare neuromuscular diseases worldwide.
